Evidence map›Paper›PMID 42645535›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Sarcopenia: diagnosis, clinical implications, and treatment].

Stephan von Haehling, Christine A F von Arnim

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephan von HaehlingKlinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland. stephan.von.haehling@web.de.
Christine A F von ArnimDZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung), Standort Niedersachsen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is a progressive skeletal muscle disorder characterized by loss of muscle strength, muscle mass, and physical performance. Its clinical relevance is increasing with population ageing. According to the revised consensus of the European Working Group on Sarcopenia in Older People (EWGSOP2), muscle strength is central to diagnosis. The Sarcopenia Screening Questionnaire (SARC-F) and handgrip strength are suitable screening tools, while muscle mass assessed by dual-energy X‑ray absorptiometry (DEXA) or bioelectrical impedance analysis and functional tests support confirmation and severity grading. Biomarkers may complement risk stratification but do not replace functional assessment. Progressive resistance training is the most effective intervention, supported by protein intake of 1.2-1.5 g/kg body weight per day and correction of vitamin D deficiency. No specific pharmacological treatment is currently approved. Prevention includes regular physical activity, adequate nutrition, treatment of comorbidities, and early mobilisation. Sarcopenia is common, prognostically relevant, and treatable when recognised early.

Indexed as

SarcopeniaAbsorptiometry, PhotonAgedBiomarkersHand StrengthHumansMuscle StrengthResistance TrainingSurveys and QuestionnairesBiomarkersDietary intake/proteinsMuscle strengthResistance trainingSarcopenia/biomarkersSarcopenia/prevention

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.